Acute myeloid leukaemia (AML) is one of the most common haematological malignancies
and is increasing in frequency due to an ageing population. Whilst remission will be
achieved in up to 80% of those receiving intensive chemotherapy, the main variables
precluding cure are the treatment-related mortality and relapse rates. Decisions on
intensification, de-escalation and allografting rely on the ability to divide an apparently
homogeneous group according to risk. A wide range of clinical, cytogenetic and molecular …